Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK (January 31, 2023)—The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the
8 Things to Know about Drug-Resistant Tuberculosis
By: Sandeep Juneja, Senior Vice President, Market Access Drug-resistant tuberculosis (DR-TB) forms when long, complex, outdated drug regimens are improperly
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the
TB Alliance Receives GHTC Partnership Award for Development of New TB Treatment
TB Alliance is honored to accept a 2022 Innovating for Impact Award WASHINGTON, DC (December 7, 2022)—At the sixth annual
New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually
PRETORIA (16 November, 2022)—A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will
WHO’s new TB numbers highlight an emergency in need of action
“The tuberculosis situation is urgent. TB is again the biggest single killer globally of any infectious disease, including COVID-19. “For
TB Alliance Board of Directors Appoints Two New Members
NEW YORK (Sept 19, 2022)—TB Alliance welcomes Kim Schwartz and Rasha Hibri to its Board of Directors. Their expertise will
Drug-Resistant TB Trial Results Published in New England Journal of Medicine
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development
TB Alliance Names Pietro Turilli as Head of External Affairs
NEW YORK (June 1, 2022)—TB Alliance today announced the appointment of Pietro Turilli to the position of Senior Vice President